Trial Profile
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 10 Apr 2023 Planned primary completion date changed from 1 Jan 2023 to 1 May 2023.
- 31 Aug 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jan 2023.
- 26 Oct 2021 Planned number of patients changed from 50 to 52.